FDA approves durvalumab as consolidation therapy for limited-stage small cell lung cancer

Later-Stage HumanFDA-approved for the exact stated cancer/useNot addressed

The FDA approved durvalumab (Imfinzi) as consolidation therapy for adults with limited-stage small cell lung cancer (LS-SCLC) whose disease had not progressed after concurrent platinum-based chemotherapy and radiation — based on the randomized, placebo-controlled, phase 3 ADRIATIC trial (ClinicalTrials.gov NCT03703297; primary publication DOI 10.1056/NEJMoa2404873). ADRIATIC randomized 730 patients 1:1:1 to durvalumab monotherapy, durvalumab plus tremelimumab, or placebo; only the durvalumab-monotherapy arm is part of the FDA-approved regimen. Reported median overall survival was meaningfully longer with durvalumab than placebo, with a statistically significant reduction in risk of death, and progression-free survival was also significantly longer. Immune-mediated adverse events, including pneumonitis, occurred at a higher rate with durvalumab than placebo and are an important part of this drug class’s safety profile.

What This Means

In the randomized, placebo-controlled ADRIATIC trial, durvalumab given as consolidation therapy after concurrent chemoradiotherapy meaningfully extended both overall survival and progression-free survival compared with placebo in limited-stage small cell lung cancer, supporting FDA approval of this specific consolidation regimen.

What This Doesn't Mean

This does not apply to extensive-stage SCLC, to patients whose disease already progressed after chemoradiotherapy, or to the durvalumab-plus-tremelimumab combination arm also studied in ADRIATIC — only the durvalumab-monotherapy regimen was approved. Framing this as "the first advance in decades" describes disease-context history, not a numeric trial result, and should not be presented as an additional efficacy claim.

Why It Matters

A rare, statistically significant survival benefit in a lung cancer subtype (limited-stage SCLC) that had not seen a major systemic-therapy advance in a long time — a genuine treatment-landscape change for this specific population.

Promise & Proof

Proof — strength of the evidence 5 / 5

Base score from evidence stage: Later-Stage Human.
FDA-approved for the exact stated cancer/use.

Promise — potential significance if later evidence holds up 4 / 5

Baseline — a validly-evidenced story starts here; every further point below is an explicit, checkable reason.
The record includes substantive editorial reasoning about why this discovery matters.
A distinct follow-on/confirmatory study or trial is already cited as a secondary source — the field is already building on this finding.
Targets a cancer type with historically limited effective treatment options.

These two ratings are automatically computed from this story's own structured evidence fields and are shown separately on purpose — they are never combined into one score. They describe this record, not a medical recommendation: they do not establish medical certainty, do not substitute for reading the cited sources, and are recalculated whenever the underlying evidence changes.

Population / Applicability

Studied in: Adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy — a consolidation-therapy approval, not a first-line or newly-diagnosed LS-SCLC treatment broadly, and specifically the durvalumab-monotherapy regimen, not the durvalumab-plus-tremelimumab arm also tested in the same trial. (Adults)

Immune-mediated adverse events, including pneumonitis/radiation pneumonitis, occurred at a meaningfully higher rate with durvalumab than placebo and must be disclosed as part of this drug's real safety profile, not omitted. Scope is strictly the durvalumab-monotherapy consolidation regimen after concurrent chemoradiotherapy in LS-SCLC — must not be broadened to extensive-stage SCLC or to the tremelimumab-combination arm.

Full evidence details

Study design: Randomized controlled trial
Sample size: 730

Funding & Conflicts

Trial sponsor: AstraZeneca (per multiple independent secondary sources; original disclosure statement itself not independently re-read — confirm exact wording during human review).

Regulatory status by jurisdiction

United States (FDA)

Status: FDA-approved for the exact stated cancer/use
Indication: Adults with LS-SCLC whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy, as consolidation therapy with durvalumab monotherapy.
Decision date: 2024-12-04
Source: Regulator record (opens in a new tab)

Guideline positions

Guideline

Position: Not addressed
Last verified: 2026-08-13

Primary evidence supporting this story

ADRIATIC trial primary results: durvalumab consolidation after chemoradiotherapy in LS-SCLC (NEJM) (opens in a new tab) (Peer-reviewed paper) [Peer-reviewed] 10.1056/NEJMoa2404873 Load-bearing source DOI 10.1056/NEJMoa2404873, PMID 39268857
ADRIATIC trial primary results: durvalumab consolidation after chemoradiotherapy in LS-SCLC (NEJM). DOI 10.1056/NEJMoa2404873, PMID 39268857.

Additional context

ADRIATIC trial registry (opens in a new tab) (Clinical-trial registry) NCT03703297 NCT03703297
ADRIATIC trial registry. NCT03703297.

Why Should I Trust This?

1 source at Tier 2 — Peer-reviewed primary research, trial registries, regulatory documents, official conference abstracts
Last reviewed: 2026-08-13

This panel summarizes real, checkable facts about this record's own sources and review status — it is not a trust score, and reading it is not a substitute for reading the cited sources yourself.

Discovery Timeline

Every recorded change to this record's content or publication status, in order.

2026-08-13 Status change — Status changed from "Legacy / Unverified" to "In editorial review".
2026-08-13 Status change — Status changed from "In editorial review" to "Verified".

Last reviewed 2026-08-13